Physician profile
Mark Akselrud
NPI 1811999766
$1,760.61
in general payments reported to CMS, 2019-2025
19 companies · $21.61 in 2025
The $21.61 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $374 · 2021: $341 · 2022: $233 · 2023: $189 · 2024: $17.49 · 2025: $21.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $228.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $228.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $432.28 | 2019-2021 | |
| Novo Nordisk INC | $357.94 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $163.94 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $135.75 | 2019-2022 | |
| Lilly USA, LLC | $117.42 | 2019-2023 | Jardiance, Emgality |
| Abbvie INC. | $108.94 | 2021-2025 | |
| Amarin Pharma, INC. | $78.94 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $58.29 | 2020-2023 | Xifaxan |
| Allergan, INC. | $57.86 | 2019-2020 | |
| Amgen INC. | $48.61 | 2019-2023 | Repatha |
| Pfizer INC. | $33.46 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $25.78 | 2023 | Abilify Maintena |
| E.R. Squibb & Sons, L.L.C. | $22.83 | 2023 | |
| Astellas Pharma US INC | $22.03 | 2019 | |
| Arbor Pharmaceuticals, INC. | $21.66 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cook Medical LLC | $20.85 | 2021 | |
| Sunovion Pharmaceuticals INC. | $18.61 | 2019 | |
| Medtronic, INC. | $18.56 | 2023 | Intellis Adaptivestim |
| Astrazeneca Pharmaceuticals Lp | $16.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Akselrud listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.